Jan 26, 2021
Hot on the heels, Aurinia launches its drug in the Lupus market after GSK Aurinia Pharmaceuticals has recently got the USFDA approval for its Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active Lupus nephritis (LN). Lupkynis is the first o...
Read More...
Jan 25, 2021
Having a strong immune system, flourished with properly working immune cells is the ultimate key to surviving a healthy life. However, what if a person is in possession of overactive immune cells? It leads to improper functioning of the immune system, confusing internal organs as foreign invaders thus attacking the...
Read More...
Jan 22, 2021
The launch of a novel drug in the market is not less than a celebration in the pharmaceutical and healthcare market; however, it also brings the real challenge of sustenance in the market. Similar is the picture of the Thrombocytopenia Drugs Market. Thrombocytopenia pipeline possesses potential drugs in mid-stage d...
Read More...
Jan 21, 2021
Unshackling the TP53 in leukaemia with a novel combination approach. Drugs that target the cancer-promoting proteins MDM2 and BET have been attempted in acute myeloid leukaemia (AML) and have not been all that effective on their own. However, they might be useful if they were combined. Researchers...
Read More...
Jan 20, 2021
Mental health today is a global burden causing a significant number of deaths. It is rapidly increasing and contributing to ill health in both developed and developing countries. According to Jürgen Rehm et al., “mental and addictive disorders affected more than 1 billion people globally in 2016. They caused ...
Read More...
Jan 20, 2021
Overcoming Anxiety in the pandemic times!! The past year has been a tough journey for all of us. It has taught us many lessons that are going to stay with us for the whole of our lives. Thus, DelveInsight has decided to take you all on a ride full of experiences - some bitter and some sweet - yet with the power ...
Read More...
Jan 19, 2021
Biohaven's Troriluzole Dwindles Again In Alzheimer’s After Anxiety Biohaven Pharmaceuticals had put too much faith in its third-generation prodrug, Troriluzole. The company has tested the efficacy of the drug in more than one indication, including generalized anxiety disorder (GAD), obsessive-compulsive di...
Read More...
Jan 18, 2021
Angelman syndrome (AS) is a complex genetic rare disorder that affects the nervous system. The first sign of a child suffering from Angelman syndrome is a delay in development, such as the inability to sit without support or making incoherent babbling sounds. The hallmarks of the syndrome constitute severe physical...
Read More...
Jan 15, 2021
Hallux Valgus, also know as Bunion, is the most common forefoot problem in adults. It is the most common pathologic entity of the big toe. It refers to the progressive swelling of the soft tissue. Hallux valgus has been reported to affect approximately 23% of the adult population aged 18 to 65 years global...
Read More...
Jan 14, 2021
Gilead and Vir Biotechnology Establish Clinical Collaboration Gilead Sciences, Inc. and Vir Biotechnology, Inc. announced that the companies have entered into a clinical collaboration to assess novel therapeutic combination strategies to develop a functional remedy for chronic hepatitis B virus (HBV). T...
Read More...